Dr. Reddy’s Q3 Review: Muted Growth In India, U.S. Generics Disappoints: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We reduce our estimate by 2-5% for FY21-23E due to delay in launch of key molecules (gCopaxone, gVascepa and gNuvaring) and also reduce benefit from gRevlimid to Rs 194 per share (earlier Rs 262) over FY23E-26E on possibility of BMS entering into settlement agreement with few more generic players for FY23E launch.
The company recently received another complete response letter for gCopaxone, which would delay the launch by four to six months, while a new generic (Teva) launch of Nuvaring increases further competitive intensity.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.